| Survival group (n = 26) | Mortality group (n = 18) | P |
---|---|---|---|
age | 61.1 ± 10.8 | 65.7 ± 11.9 | 0.20 |
Male/female | 23 (89%) | 16 (89%) | 0.97 |
Hypertension | 15 (58%) | 11 (61%) | 0.82 |
diabetes mellitus | 7 (25%) | 6 (33%) | 0.54 |
eGFR(ml/min1.73m2) | 60 ± 22 | 61 ± 25 | 0.90 |
LDL level (mmol/L) | 3.36 ± 0.87 | 3.18 ± 0.71 | 0.53 |
Cardiogenic shock | 9 (35%) | 16 (89%) | 0.00* |
Onset-to-FMC (min) | 227 ± 114 | 210 ± 132 | 0.69 |
Collateral perfusion | 14 (54%) | 4 (22%) | 0.04* |
Final TIMI 3 flow | 18 (69%) | 6 (33%) | 0.02* |
IABP | Â | Â | 0.08 |
 Positioned before PCI | 2 | 5 |  |
 Positioned during PCI | 22 | 12 |  |
Mechanical ventilation | 8 (31%) | 9 (50%) | 0.20 |
Thrombus aspiration | 7 (27%) | 5 (28%) | 0.95 |
RCA severe stenosis | 7 (27%) | 4 (22%) | 0.72 |
RCA PCI simultaneously | 2 (8%) | 1 (6%) | 0.75 |
LM site | Â | Â | 0.73 |
 Ostium | - | - |  |
 Body | 16 | 12 |  |
 Bifurcation | 10 | 6 |  |
Antiplatelet drug | |||
 Clopidogrel | 8 (31%) | 7 (39%) | 0.58 |
 Ticagrelor | 18 (69%) | 11 (61%) |  |
 GP IIb/IIIa inhibitors | 18 (69%) | 13 (72%) | 0.83 |